JHJohn B. Harley

John B. Harley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John B. Harley has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin F. Bruner

    Department of Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America

    1 shared publication
  • Colin C. Edgerton

    Walter Reed Army Medical Center, Washington, District of Columbia, United States of America

    1 shared publication
  • Judith A. James

    Department of Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America

    1 shared publication
  • Judith A. James

    Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA

    1 shared publication
  • Latisha D. Heinlen

    Department of Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America

    1 shared publication
  • Lauren L. Ritterhouse

    Department of Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America

    1 shared publication

Latest Publications

  • Open Access

    60 kD Ro and nRNP A Frequently Initiate Human Lupus Autoimmunity

    by Latisha D. Heinlen, Micah T. McClain, Lauren L. Ritterhouse, Benjamin F. Bruner, Colin C. Edgerton, Michael P. Keith, Judith A. James, John B. Harley

    Systemic lupus erythematosus (SLE) is a clinically heterogeneous, humoral autoimmune disorder. The unifying feature among SLE patients is the production of large quantities of autoantibodies. Serum samples from 129 patients collected before the onset of SLE and while in the United States military were evaluated for early pre-clinical serologic events. The first available positive serum sample frequently already contained multiple autoantibody specificities (65%). However, in 34 SLE patients the earliest pre-clinical serum sample positive for any detectable common autoantibody bound only a single autoantigen, most commonly 60 kD Ro (29%), nRNP A (24%), anti-phospholipids (18%) or rheumatoid factor (15%). We identified several recurrent patterns of autoantibody onset using these pre-diagnostic samples. In the serum samples available, anti-nRNP A appeared before or simultaneously with anti-nRNP 70 K in 96% of the patients who had both autoantibodies at diagnosis. Anti-60 kD Ro antibodies appeared before or simultaneously with anti-La (98%) or anti-52 kD Ro (95%). The autoantibody response in SLE patients begins simply, often binding a single specific autoantigen years before disease onset, followed by epitope spreading to additional autoantigenic specificities that are accrued in recurring patterns.


  • IL-7Rα and multiple sclerosis risk

    by John B Harley


    • 1 January 2006
      • Vol. 64, 45-50

    Epstein-Barr virus infection induces lupus autoimmunity.

    by John B Harley, Judith A James

    Systemic lupus erythematosus (SLE or lupus) is a systemic autoimmune disease characterized by a constellation of varied clinical presentations, although the nearly universal presence of autoantibodies is a salient unifying feature. Ongoing research efforts focus on understanding the complex combination of genetic and environmental factors that lead to SLE in select individuals. Our previous work has demonstrated that years before diagnosis abnormal autoantibody responses are present in the sera of patients who will subsequently develop lupus and, further, that the initial targets of two of these key responses (anti-Sm B' and anti-60 kD Ro alone) have been identified for some patients. Indeed, our results suggest that the first lupus-specific autoantibodies arise from particular antibodies directed against Epstein-Barr virus Nuclear Antigen-1 (EBNA-1) and that infection with Epstein-Barr virus (EBV) is an environmental risk factor for lupus. The predicted sequence of events is normal immunity, followed by Epstein- Barr virus infection, the generation of anti-EBNA-1 antibodies, then followed by those particular anti-EBNA-1 antibodies that also bind lupus-specific autoantigens (Sm or Ro), followed by the development of more complex autoimmune responses, and, finally, culminating in clinical disease. Studies from others and those underway suggest that lupus patients have unusual immune responses to Epstein-Barr virus. In aggregate, these results are consistent with an immune response against Epstein-Barr virus being important in at least some patients for the initiation of lupus autoimmunity.